The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...

but MSD (known as Merck & Co in the US and Canada) paid $20 million upfront to Alteogen, with up to $432 million in back-end milestones. Enhertu is fast becoming a major growth product for Daiichi ...

as well as in Canada. AZ estimates that around 1,000 patients in England alone will now miss out on treatment with Enhertu, and patient organisation Breast Cancer NOW described the outcome as a ...

The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. In late November 2023 AstraZeneca’s chief executive Pascal Soriot flew from Sydney to London to deliver a ...

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer ...

Alliance revenues included $392 million from Daiichi Sankyo for Enhertu and $133 million of ... However, generic competition in Canada hurt sales. Farxiga sales marginally missed both the Zacks ...

It said the taxes related to its Imfinzi and Imjudo drugs, but could possibly widen to breast cancer drug Enhertu as well ... He also confirmed that tariffs on Canada, Mexico and China being ...

EMA committee recommends approval of AstraZeneca’s Imfinzi in combo with chemotherapy to treat resectable non-small cell lung cancer ...